The Food and Drug Administration approved the CyberKnife to treat tumors in the head, neck and upper spine in 1999 and tumors anywhere in the body in 2001.
Globally, more than 200,000 patients have been treated with CyberKnife. Additionally, numerous clinical trials and comparative effectiveness studies have been performed and are currently underway to evaluate the effects of radiosurgery administered by CyberKnife.
Our physicians – along with other CyberKnife users around the world – collaborate to develop protocols for treating several types of malignant and benign tumors in the brain, spine, lungs, liver, pancreas, kidneys, prostate, bone and eye.
More detailed information on the types of tumors and medical conditions treated by CyberKnife is available in the Conditions Treated section of this site.